<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1910234361
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROFINAL Pediatric Suspension
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IBUPROFEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        110
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Profinal</strong> belongs to a group of medicines called anti-inflammatory pain killers.</p><p>The active ingredient in <strong>Profinal</strong> is ibuprofen and each teaspoonful (5mL) contains 100mg of Ibuprofen.</p><p>It can be used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis (including juvenile rheumatoid arthritis or Still&#39;s disease), arthritis of the spine (ankylosing spondylitis), swollen joints, frozen shoulder, bursitis, tendonitis, tenosynovitis, lower back pain, sprains and strains.</p><p><strong>Profinal</strong> can also be used to lower temperature and to treat other painful conditions such as toothache, pain after operations, period pain and headache, including migraine and to reduce fever in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Profinal:</strong></p><p>-&nbsp; If you are sensitive (allergic) to any of the ingredients in the suspension. These are listed in Section 6:further information</p><p>-&nbsp; If you are previously experienced stomach bleeding or perforation after taking ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs)</p><p>-&nbsp; If you are currently have a peptic ulcer (ulcer in your stomach or duodenum) or bleeding in your stomach, or have had two or more episodes of peptic ulcers, stomach bleeding or perforation in the past</p><p>-&nbsp; If you have a history of inflammatory bowel disease (ulcerative colitis, Crohn&rsquo;s disease)</p><p>-&nbsp; suffer from severe heart failure, liver failure or kidney failure</p><p>-&nbsp; If you have a condition which increases your tendency to bleeding</p><p>-&nbsp; If you are sensitive (allergic) or previously had an allergic reaction or suffered from wheezing after taking ibuprofen, aspirin or other anti-inflammatory pain killers</p><p>-&nbsp; If you are in the third trimester (last 3 months) of pregnancy</p><p>-&nbsp; If you have fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency</p><p>Do not take <strong>Profinal</strong> if any of the above applies to you. If you are not sure, talk to your doctor, pharmacist or nurse.</p><p><strong>Warnings and precautions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Cardiovascular Risk</strong></p><p>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.</p><p><strong>Gastrointestinal Risk</strong></p><p>NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.</p></td></tr></tbody></table><p><strong>Talk to your doctor, pharmacist or nurse before taking Profinal:</strong></p><p>-&nbsp; If you have an infection - please see heading &ldquo;Infections&rdquo; below.</p><p>-&nbsp; If you have, or previously suffered from bronchial asthma, chronic rhinitis or allergic diseases</p><p>-&nbsp; If you suffer from liver, kidney or heart disease</p><p>-&nbsp; If you suffer from high blood pressure (hypertension)</p><p>-&nbsp; If you are elderly &ndash; elderly people are more prone to side effects to NSAIDs, particularly stomach bleeding and perforation which can be fatal</p><p>-&nbsp; If you have been told by your doctor that you have an intolerance to some sugars</p><p>-&nbsp; If you have, or you previously had a stomach ulcer, stomach bleeding or other gastric complaint</p><p>-&nbsp; If you are dehydrated- there is a risk of renal impairment in dehydrated children, adolescents and the elderly</p><p>-&nbsp; If you have a condition which increases your tendency to bleeding or have bleeding in the skull &ndash; please see above</p><p>-&nbsp; If you have lupus or a connective tissue disease (autoimmune diseases affecting connective tissue)</p><p>-&nbsp; During chicken pox (varicella) it is advisable to avoid the use of ibuprofen.</p><p><strong>Infections </strong></p><p>Ibuprofen may hide signs of infections such as fever and pain. It is therefore possible Ibuprofen may delay appropriate treatment of infection, which may lead to an increased risk of complications. This has been observed in pneumonia caused by bacteria and bacterial skin infections related to chickenpox. If you take this medicine while you have an infection and your symptoms of the infection persist or worsen, consult a doctor without delay.</p><p><strong>Heart attack and stroke</strong></p><p>Anti-inflammatory/pain-killer medicines like <strong>Profinal</strong> may be associated with a small increased risk of heart attack or stroke, particularly when used at high doses. Do not exceed the recommended dose or duration of treatment.</p><p>You should discuss your treatment with your doctor or pharmacist before taking <strong>Profinal</strong> if you:</p><p>-&nbsp; have heart problems including heart failure, angina (chest pain) or you have had a heart attack, bypass surgery or peripheral artery disease (poor circulation in the legs or feet due to narrow or blocked arteries), or any kind of stroke (including &lsquo;mini-stroke&rsquo; or transient ischaemic attack &ldquo;TIA&rdquo;).</p><p>-&nbsp; have high blood pressure, diabetes, high cholesterol, have a family history of heart disease or stroke, or if you are a smoker.</p><p><strong>Skin reactions</strong></p><p>Serious skin reactions have been reported in association with ibuprofen treatment. You should stop taking <strong>Profinal</strong> and seek medical attention immediately, if you develop any skin rash, lesions of the mucous membranes,</p><p>blisters or other signs of allergy since this can be the first signs of a very serious skin reaction. See section 4.</p><p><strong>Children and adolescents</strong></p><p>There is a risk of renal impairment in dehydrated children and adolescents.</p><p><strong>Other medicines and Profinal</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because <strong>Profinal</strong> can affect the way some other medicines work.</p><p>Also some other medicines can affect the way <strong>Profinal</strong> works.</p><p><strong>Profinal</strong> may affect or be affected by some medicines. For example:</p><p>-&nbsp; medicines that are anti-coagulants (i.e. thin blood/prevent clotting e.g. aspirin/acetylsalicylic acid, warfarin, ticlopidine)</p><p>-&nbsp; medicines that reduce high blood pressure (ACE-inhibitors such as captopril, beta-blockers such as atenolol or angiotensin-II receptor antagonists such as losartan)</p><p>Some other medicines may affect or be affected by treatment with <strong>Profinal</strong>. You should therefore always seek the advice of your doctor or pharmacist before you use <strong>Profinal</strong> with other medicines.</p><p>In particular you should tell your doctor or pharmacist if you are taking any of the following medicines in addition to those mentioned above:</p><p>-&nbsp; any medicines used to treat high blood pressure (see above)</p><p>-&nbsp; any medicines to treat heart conditions (e.g. diuretics such as bendroflumethiazide or furosemide or cardiac glycosides such as digoxin)</p><p>-&nbsp; any anti-coagulants or anti-platelet medicines (see above)</p><p>-&nbsp; lithium or selective serotonin reuptake inhibitors (SSRIs) (used to treat depression)</p><p>-&nbsp; a medicine called zidovudine (an anti-viral drug)</p><p>-&nbsp; a medicine called methotrexate (used to treat some forms of cancer)</p><p>-&nbsp; medicines called cyclosporin or tacrolimus (immunosuppressants used following organ transplant or in autoimmune conditions such as psoriasis, eczema)</p><p>-&nbsp; any other NSAIDs or anti-inflammatory pain killers, including aspirin and the group of drugs known as COX-2 inhibitors such as celecoxib and lumiracoxib</p><p>-&nbsp; any corticosteroids (e.g. hydrocortisone, betamethasone, prednisolone, used to treat inflammatory conditions)</p><p>-&nbsp; a certain type of antibiotic, known as quinolone antibiotics (e.g. ciprofloxacin and levofloxacin)</p><p>-&nbsp; a certain type of antibiotic known as aminoglycosides</p><p>-&nbsp; mifepristone</p><p>-&nbsp; any oral medicines used to treat diabetes (e.g. metformin, or any sulphonylurea medicines)</p><p>-&nbsp; a herbal remedy called ginkgo bilboa (there is a chance that you may bleed more easily if you are taking ibuprofen and ginkgo biloba at the same time).</p><p>-&nbsp; cholestyramine (used to treat high cholesterol levels)</p><p>-&nbsp; voriconazole or fluconazole (anti-fungal drugs)</p><p><strong>Profinal with alcohol</strong></p><p>Medicines such as <strong>Profinal</strong> may cause dizziness, drowsiness, tiredness and problems with vision. Consumption of alcohol may increase these effects.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>Please tell your doctor if you are, or think you are, pregnant. <strong>Profinal</strong> is not recommended during the first and second trimesters (first 6 months) of pregnancy unless clearly necessary and should not be taken during the third trimester (last 3 months) of pregnancy.</p><p><strong>Profinal</strong> is not recommended while breast-feeding.</p><p><strong>Profinal</strong> may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p><strong>Driving and using machines</strong></p><p>Medicines such as <strong>Profinal</strong> may cause dizziness, drowsiness, tiredness and problems with vision. If affected, you should not drive or operate machines. Also you should not do anything else where you need to be alert. This particularly applies in combination with alcohol.</p><p><strong>What else do you need to know about Profinal</strong></p><p>Do not take <strong>Profinal</strong> if you are allergic to aspirin. If you develop an unexpected skin rash, sore eyes, sore mouth or difficulty breathing whilst taking the medicine, stop taking it and contact your doctor for advice.</p><p><strong>Important information about some of the ingredients of Profinal</strong></p><p><strong>Profinal contains:</strong></p><p>Sorbitol, which may have a mild laxative effect.</p><p>Sucrose, this should be taken into account in patients with diabetes mellitus. May be harmful to the teeth</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The lowest effective dose should be used for the shortest duration necessary to relieve symptoms. If you have an infection, consult a doctor without delay if symptoms (such as fever and pain) persist or worsen (see section 2).</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Profinal</strong> can be taken with a little water, preferably with or after food.</p><p>Remember to shake the bottle before use.</p><p>It is recommended that patients with sensitive stomachs take ibuprofen with food.</p><p><strong>The recommended dose is</strong></p><p><strong>Adults and adolescents:</strong> The usual dose is four to six 5 mL teaspoonful taken three times each day. Your doctor may choose to increase or decrease this dose depending on your symptoms, but no more than 120 mL of oral suspension (2400 mg) should be taken each day.</p><p><strong>Children:</strong> The usual dose in children is 20 mg to 30 mg per kg of bodyweight each day, in divided doses.</p><p>This can be given as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age/weight</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Single dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>3-6 months (~5-7kg)</p></td><td style="vertical-align:top"><p>Up to 3 times a day</p></td><td style="vertical-align:top"><p>2.5mL - &frac12; teaspoonful (50mg)</p></td></tr><tr><td style="vertical-align:top"><p>6-12 months (~7-10kg)</p></td><td style="vertical-align:top"><p>3 times a day</p></td><td style="vertical-align:top"><p>2.5mL - &frac12; teaspoonful (50mg)</p></td></tr><tr><td style="vertical-align:top"><p>1 to 2 years (~10-14.5kg)</p></td><td style="vertical-align:top"><p>3 to 4 times a day</p></td><td style="vertical-align:top"><p>2.5mL- &frac12; teaspoonful (50mg)</p></td></tr><tr><td style="vertical-align:top"><p>3 to 7 years (~14.5-25kg)</p></td><td style="vertical-align:top"><p>3 to 4 times a day</p></td><td style="vertical-align:top"><p>5mL - 1 teaspoonful (100mg)</p></td></tr><tr><td style="vertical-align:top"><p>8 to 12 years (~25-40kg)</p></td><td style="vertical-align:top"><p>3 to 4 times a day</p></td><td style="vertical-align:top"><p>10mL - 2 teaspoonfuls (200mg)</p></td></tr></tbody></table><p>&nbsp;</p><p>The doctor may choose to increase this dose in children with severe arthritis to 40mg/kg of bodyweight daily, if needed. In children weighing less than 30 kg, no more than 500 mg of <strong>Profinal</strong> should be given each day.</p><p><strong>Elderly:</strong> &ndash; Refer to adult dosing. If you have liver or kidney problems however, your dose may need to be modified in which case you should contact your doctor for advice.</p><p>A transient sensation of burning in the mouth or throat may occur with ibuprofen suspension.</p><p>Avoid prolonged use of any painkillers as these may result in headaches that should not be treated with increased doses of <strong>Profinal</strong>. Tell your doctor if this occurs.</p><p><strong>If you take more Profinal than you should</strong></p><p>If you take more <strong>Profinal</strong> than you should, or if children have taken this medicine by accident always contact a doctor or nearest hospital to get an opinion of the risk and advice on action to be taken.</p><p>The symptoms can include nausea, stomach pain, vomiting (may be blood steaked), headaches, ringing in the ears, confusion and shaky eye movement. At high doses, drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness and dizziness, blood in urine, cold body feeling, and breathing problems have been reported.</p><p><strong>If you forget to take Profinal</strong></p><p>-&nbsp; take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose.</p><p>-&nbsp; do not take a double dose to make up for the a forgotten one.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If any side effects become serious or if you notice any side effects that are not listed in this leaflet, please tell your doctor or pharmacist. You can minimise the risk of side effects by taking the least amount of medicine for the shortest amount of time necessary to control your symptoms.</p><p><strong>Serious side effects</strong></p><p>-&nbsp; <strong>Stop taking Profinal and see your doctor straight away if you notice any of the following side effects &ndash; you may need urgent medical attention: </strong>Severe headache, high temperature, stiffness of the neck or intolerance to bright light</p><p>-&nbsp; Pass blood in your faeces (stools/motions)</p><p>-&nbsp; Pass black tarry stools</p><p>-&nbsp; Vomit any blood or dark particles that look like coffee grounds</p><p><strong>Stop taking this medicine and tell your doctor if you notice any of the following:</strong></p><p>-&nbsp; Hypersensitivity reactions such as unexplained wheezing, shortness of breath, skin rash, itching or bruising</p><p>-&nbsp; Unexplained stomach pain or other abnormal stomach symptoms, indigestion, heartburn, feeling sick and/or vomiting</p><p>-&nbsp; Yellowing of the eyes and/or skin</p><p>-&nbsp; Severe sore throat with high fever (these may be symptoms of a condition known as agranulocytosis)</p><p>-&nbsp; Blurred or disturbed vision or seeing/hearing strange things</p><p>-&nbsp; Fluid retention (e.g. swollen ankles).</p><p>Medicines such as ibuprofen have been associated with a small increased risk of heart attack (myocardial infarction) or stroke.</p><p>Very rarely ibuprofen may cause aseptic meningitis (inflammation of the protective membrane surrounding the brain).</p><p>A severe skin reaction known as DRESS syndrome can occur. Symptoms of DRESS include: skin rash, fever, swelling of lymph nodes and an increase in eosinophils (a type of white blood cells).</p><p>A red, scaly widespread rash with bumps under the skin and blisters mainly localized on the skin folds, trunk, and upper extramities accompanied by fever at the initiation of treatment (acute generalised exanthematous pustulosis). Stop using <strong>Profinal</strong> if you develop these symptoms and seek medical attention immediately. See also section 2.</p><p>Ibuprofen may hide the signs of an underlying infection.</p><p><strong>Other side effects of this medicine may include:</strong></p><p>-&nbsp; nausea, vomiting, diarrhoea, flatulence (wind), constipation, stomach ache</p><p>-&nbsp; mouth ulcer</p><p>-&nbsp; duodenal ulcer</p><p>-&nbsp; stomach perforation</p><p>-&nbsp; increase in severity of Crohn&rsquo;s disease or colitis</p><p>-&nbsp; inflammation of the stomach lining</p><p>-&nbsp; inflammation of the pancreas</p><p>-&nbsp; burning sensation in the mouth or throat</p><p>-&nbsp; high blood pressure (hypertension)</p><p>-&nbsp; heart failure</p><p>-&nbsp; nasal stuffiness or runny nose (rhinitis)</p><p>-&nbsp; blood disorders such as a reduction in different types of cells in the blood</p><p>-&nbsp; difficulty sleeping, anxiety, depression, confusion</p><p>-&nbsp; headaches, numbness or tingling, dizziness, drowsiness, tiredness, generally feeling unwell</p><p>-&nbsp; blurred or disturbed vision, inflammation of the optic nerve</p><p>-&nbsp; balance disorder which makes you feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating (vertigo), ringing in the ears, hearing problems</p><p>-&nbsp; liver problems such as hepatitis or jaundice</p><p>-&nbsp; skin problems such as increased sensitivity to light and severe reactions (such as blistering of the skin, mouth, eyes and genitals)</p><p>-&nbsp; kidney problems, including reduced kidney function and kidney failure</p><p>&nbsp;</p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>You can also report side effects directly via:</p><p><strong>&bull;&nbsp; Saudi Arabia:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fax:</strong> +966-11-205-7662</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2340</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>SFDA Call centre:</strong> 19999</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Website:</strong> www.sfda.gov.sa/npc</p><p><strong>&bull; Other GCC States: Please contact the relevant competent authority.</strong></p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Do not take this medicine after the expiry date which is stated on the outer carton and on the inner label.</p><p>-&nbsp; Store below 30&deg;C, protected from light. After opening use within one month.</p><p>-&nbsp; Do not take this medicine if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Ibuprofen. Each teaspoonful (5mL) of the suspension contains 100mg of Ibuprofen.</p><p>The other ingredients: Sucrose, sodium benzoate, saccharin sodium, sodium EDTA, glycerol, sorbitol, xanthan gum, cellulose, polysorbate, citric acid, FD&amp;C red no. 40, all fruit flavour,strawberry flavour and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Profinal suspension is available packs containing one bottle (60mL, 110mL, or 135mL) each.  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/11/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ینتمي <strong>بروفینال</strong> إلى مجموعة من الأدویة المعروفة باسم مضادات الالتهاب المسكنة للآلام.</p><p dir="RTL">إن المادة الفعالة في <strong>بروفینال</strong> هي آیبوبروفین و تحتوي كل ملعقة صغیرة ( ٥ مللیلتر) من المعلق على ١٠٠ ملغم من آیبوبروفین.</p><p dir="RTL">ومن الممكن أن یستعمل هذا الدواء لتخفیف الألم والالتهاب في حالات مثل التهاب المفصل التنكسي، التهاب المفاصل الروماتویدي (بما في ذلك التهاب المفاصل الروماتویدي الصبیاني أو داء ستیل)، التهاب المفاصل في العمود الفقري (التهاب الفقار القسطي)، تورم المفاصل، الكتف المتجمد، الالتهاب الكیسي الزلالي، التهاب الأوتار، التهاب غمد الوتر، الألم في أسفل الظهر، وحالات الالتواء والإجهاد.</p><p dir="RTL">كما قد یستعمل <strong>بروفینال</strong> لخفض درجة الحرارة ولعلاج الحالات الأخرى المصحوبة بألم مثل ألم الأسنان، الألم الذي یحدث عقب العملیات الجراحیة، وآلام الدورة الشهریة والصداع، بما في ذلك الصداع النصفي، ولتقلیل الحمى لدى الأطفال.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یجب علیك عدم تناول <strong>بروفینال</strong> في الحالات التالیة:</p><p dir="RTL">-&nbsp; إذا كنت تعاني من الحساسیة تجاه أياً من مكونات هذا الدواء. المذكورة في البند رقم ٦: &quot;معلومات إضافیة&quot;.</p><p dir="RTL">-&nbsp; إذا عانیت مسبقاً من نزیف أو انثقاب المعدة بعد تناول آیبوبروفین أو الأدویة الغیر ستیرویدیة المضادة للالتهابات الأخرى.</p><p dir="RTL">-&nbsp; إذا كنت تعاني في الوقت الحالي من قرحة هضمیة (قرحة في المعدة أو الإثنى عشر) أو نزیف في المعدة، أو عانیت مسبقاً من حدوث نوبتين أو أكثر للقرحة الهضمیة، نزیف أو انثقاب المعدة.</p><p dir="RTL">-&nbsp; إذا كان لدیك تاریخ مرضي مع الإصابة بداء الأمعاء الالتهابي (التهاب القولون التقرحي، ومرض كرون).</p><p dir="RTL">-&nbsp; إذا كنت تعاني من فشل قلبي حاد، فشل كبدي، أو فشل كلوي.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من حالة مرضیة تزید من قابلیة حدوث نزیف.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من الحساسیة أو عانیت مسبقاً من تفاعلات تحسسیة أو عانیت من أزیز بعد تناول آیبوبروفین، أسبرين أو أياً من الأدویة الأخرى المضادة للالتهاب والمسكنة للألم.</p><p dir="RTL">-&nbsp; إذا كنت في الثلث الأخیر (الأشهر الثلاث الأخیرة) من الحمل.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من عدم القدرة على تحمل الفركتوز، سوء امتصاص الجلوكوز-الجالاكتوز أو عوز سكراز إیزومالتاز.</p><p dir="RTL">-&nbsp; یجب عدم تناول <strong>بروفینال</strong> في حال أياً من مما ذكر أعلاه ینطبق علیك. یرجى منك التحدث إلى طبیبك المعالج، الصیدلي الذي تتعامل معه أو الممرض إذا لم تكن متأكداً من ذلك.</p><p dir="RTL"><strong>تحذیرات واحتیاطات</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المخاطر على القلب والأوعیة الدمویة</strong></p><p dir="RTL">قد تزید الأدویة الغیر ستیرویدیة المضادة للالتهابات من خطر حدوث تجلطات خطیرة في القلب والأوعیة الدمویة، احتشاء العضلة القلبیة، والسكتة الدماغیة التي قد تؤدي إلى الوفاة. قد یزداد هذا الخطر في حال الاستمرار في تناول هذا الدواء لفترة طویلة، وقد یكون هذا الخطر أكبر في حالة المرضى الذین یعانون من أو المعرضین للإصابة بأمراض القلب والأوعیة الدمویة. یجب عدم تناول الأدویة الغیر ستیرویدیة المضادة للالتهابات لعلاج الآلام التي تحدث في الفترة التي تسبق أو تلي إجراء العملیات الجراحیة التي تخص ترقیع الشرایین التاجیة.</p><p dir="RTL"><strong>المخاطر على القناة الهضمیة</strong></p><p dir="RTL">قد تزید الأدویة الغیر ستیرویدیة المضادة للالتهابات من خطر حدوث تأثیرات سلبیة خطیرة على القناة الهضمیة والتي تشمل نزیف، قرحة، وثقب في المعدة أو الأمعاء والذي قد یؤدي إلى الوفاة. قد تحدث هذه التأثیرات في أي وقت أثناء فترة تناول هذا الدواء ومن دون ظهور أي أعراض تحذیریة، وعلى الأغلب فإن المرضى المسنین یكونون الأكثر عرضة للإصابة بتلك التأثیرات الخطیرة.</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض في الحالات التالية:</p><p dir="RTL">-&nbsp; إذا كنت تعاني من العدوى - يرجى النظر إلى الفقرة أدناه &quot;العدوى&quot;.</p><p dir="RTL">-&nbsp; إذا كنت تعاني أو عانیت مسبقاً من الربو القصبي، التهاب الأنف المزمن أو اضطرابات الحساسیة.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من اضطرابات الكبد، الكلى، أو القلب.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp; إذا كنت من فئة كبار السن &ndash; فئة كبار السن هم الأكثر عرضة للإصابة بالتأثیرات الجانبیة الناجمة عن الأدویة الغیر ستیرویدیة المضادة للالتهابات، بصفة خاصة حدوث نزیف أو انثقاب المعدة حیث أن هذه التأثیرات قد تؤدي إلى الوفاة.</p><p dir="RTL">-&nbsp; إذا أخبرك طبیبك المعالج مسبقاً بأنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p><p dir="RTL">-&nbsp; إذا كنت تعاني، أو عانیت مسبقاً من قرحة المعدة، حدوث نزیف في المعدة أو مشاكل هضمیة أخرى.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من الجفاف &ndash; إن الأطفال، المراهقين وفئة كبار السن الذین یعانون من الجفاف معرضون لخطر حدوث قصور في وظائف الكلى.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من حالة مرضیة تزید من قابلیة حدوث نزیف أو كنت تعاني من نزیف في الجمجمة- یرجى منك النظر إلى ما ذكر أعلاه.</p><p dir="RTL">-&nbsp; إذا كنت تعاني من داء الذئبة أو اضطرابات النسیج الضام (أمراض المناعة الذاتیة التي تؤثر على النسیج الضام).</p><p dir="RTL">-&nbsp; يفضل تجنب استعمال الآيبوبروفين أثناء فترة المعاناة من جديري الماء (الحماق).</p><p dir="RTL"><strong>العدوى </strong></p><p dir="RTL">قد يعمل آيبوبروفين على إخفاء علامات حدوث العدوى على سبيل المثال الحمى والألم. لذلك، من المحتمل أن يؤخر آيبوبروفين تلقي العلاج الملائم للعدوى، مما قد يؤدي إلى خطر حدوث مضاعفات. لقد لوحظ حدوث ذلك في حالات الالتهاب الرئوي الناجم عن البكتيريا وحالات عدوى الجلد البكتيرية المرتبطة بجديري الماء. يرجى منك استشارة طبيبك المعالج على الفور، إذا كنت تتناول هذا الدواء أثناء الإصابة بالعدوى واستمرار أو تفاقم أعراض العدوى لديك.&nbsp;</p><p dir="RTL"><strong>النوبة القلبیة والسكتة الدماغیة</strong></p><p dir="RTL">إن الأدویة المضادة للالتهاب/المسكنة للآلام على سبیل المثال <strong>بروفینال</strong> قد یصاحب تناولها زیادة خطر حدوث النوبات القلبیة أو السكتة الدماغیة بصورة طفیفة،</p><p dir="RTL">وبصفة خاصة عند تناول جرعات كبیرة. یجب عدم تجاوز مقدار الجرعة الموصى بها أو مدة العلاج المحددة لك.</p><p dir="RTL">یرجى منك مناقشة مع طبیبك المعالج أو الصیدلي الذي تتعامل معه حول العلاج الخاص بك قبل تناول <strong>بروفینال</strong> في الحالات التالیة:</p><p dir="RTL">-&nbsp; إذا كنت تعاني من مشاكل في القلب بما في ذلك قصور القلب، الذبحة الصدریة (ألم في الصدر) أو عانیت مسبقاً من النوبة القلبیة، خضعت لجراحة فتح مجرى جانبي (جراحة المجازة) أو مرض الشریان المحیطي (ضعف الدورة الدمویة في القدمین أو الساقین الناجمة عن ضیق أو انسداد الشرایین)، أو أي نوع من أنواع السكتة الدماغیة (بما في ذلك النوبة الإقفاریة العابرة).</p><p dir="RTL">-&nbsp; إذا كنت تعاني من ارتفاع ضغط الدم، داء السكري أو ارتفاع مستوى الكولیسترول في الدم، لدیك تاریخ عائلي مع الإصابة باضطرابات القلب أو السكتة الدماغیة أو إذا كنت مدخناً.</p><p dir="RTL"><strong>التفاعلات الجلدية </strong></p><p dir="RTL">سجل حدوث تفاعلات جلدية خطيرة المصاحبة لتلقي العلاج باستخدام آيبوبروفين. يجب عليك التوقف عن تناول بروفينال وطلب الرعاية الطبية على الفور، في حال حدوث أي طفح جلدي، آفات الأغشية المخاطية، تقرحات أو أية علامات أخرى للحساسية، حيث قد يكون ذلك أول علامات التي تدل على حدوث التفاعلات الجلدية الخطيرة جداً. انظر البند رقم 4.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">إن الأطفال والمراهقين الذین یعانون من الجفاف معرضون لخطر حدوث قصور في وظائف الكلى.</p><p dir="RTL"><strong>تناول الأدویة الأخرى بالتزامن مع بروفینال</strong></p><p dir="RTL">یرجى منك إخبار طبیبك المعالج أو الصیدلي الذي تتعامل معه، إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أیة أدویة أخرى. حیث قد یؤثر <strong>بروفینال</strong> على آلیة عمل بعض الأدوية الأخرى كما قد تؤثر بعض الأدوية الأخرى على آلیة عمل <strong>بروفینال</strong>.</p><p dir="RTL">قد یؤثر <strong>بروفینال</strong> على بعض الأدویة أو قد یتأثر من بعض الأدویة. على سبیل المثال:</p><p dir="RTL">-&nbsp; الأدویة التي تمنع تجلط الدم (بمعنى ترقق الدم/تمنع التخثر على سبیل المثال الأسبرین/حمض أسيتيل سالیسیلك، وارفارین، تيكلوبيدين).</p><p dir="RTL">-&nbsp; الأدویة التي تقلل من ارتفاع ضغط الدم (مثبطات إنزیم محول للأنجیوتنسین على سبیل المثال كابتوبریل،غالقات مستقبلات بیتا على سبیل المثال أتینولول أو مضادات مستقبلات الأنجيوتنسين II على سبيل المثال لوسارتان).</p><p dir="RTL">بعض الأدویة الأخرى التي قد تؤثر أو تتأثر بالعلاج مع <strong>بروفینال</strong>. لذلك یجب علیك طلب المشورة الطبية دائماً من طبیبك المعالج أو الصیدلي الذي تتعامل معه قبل تناول <strong>بروفینال</strong> بالتزامن مع الأدویة الأخرى.</p><p dir="RTL">بصفة خاصة، یجب علیك إخبار طبیبك المعالج أو الصیدلي الذي تتعامل معه إذا كنت تتناول أياً من الأدویة التالیة بالإضافة إلى الأدویة المذكورة أعلاه:</p><p dir="RTL">-&nbsp; أیة أدویة تستخدم لعلاج ارتفاع ضغط الدم (انظرأعلاه)</p><p dir="RTL">-&nbsp; أیة أدوية تستخدم لعلاج حالات القلب (مثل مدرات البول على سبیل المثال بندروفلومیثیازید أو فوروسیمید أو جلیكوسیدات القلبیة على سبیل المثال الدیجوكسین)</p><p dir="RTL">-&nbsp; أیة أدویة مضادة للتجلط أو مضادة لتكدس الصفائح الدمویة (انظر أعلاه)</p><p dir="RTL">-&nbsp; اللیثیوم أو مثبطات إعادة امتصاص السیروتونین الانتقائیة (تستخدم لعلاج الاكتئاب)</p><p dir="RTL">-&nbsp; دواء یعرف باسم زیدوفودین (دواء مضاد للفیروسات)</p><p dir="RTL">-&nbsp; دواء یعرف باسم میثوتركسیت (یستخدم لعلاج بعض أنواع السرطان)</p><p dir="RTL">-&nbsp; دواء یعرف باسم سیكلوسبورین أو تاكرولیموس(مثبط للمناعة یستخدم بعد زراعة الأعضاء أو في حالات أمراض المناعة الذاتیة على سبیل المثال الصدفیة والأكزیما)</p><p dir="RTL">-&nbsp; أياً من الأدویة الغیر ستیرویدیة المضادة للالتهابات والمسكنة للألم، بما في ذلك الأسبرین ومجموعة من الأدویة التي تعرف باسم مثبطات كوكس- ٢ على سبیل المثال سیلیكوكسیب ولومیراكوكسیب</p><p dir="RTL">-&nbsp; أياً من الأدویة من مجموعة كورتیكوستیرویدات (على سبیل المثال هیدروكورتیزون، بیتامیثازون، بریدنیزولون، تستخدم لعلاج حالات الالتهابات)</p><p dir="RTL">-&nbsp; مجموعة معینة من المضادات الحیویة تعرف باسم المضادات الحیویة من فئة الكوینولون (على سبیل المثال سیبروفلوكساسین ولیفوفلوكساسین)</p><p dir="RTL">-&nbsp; مجموعة معینة من المضادات الحیویة تعرف باسم الأمینوجلایكوسیدات</p><p dir="RTL">-&nbsp; میفیبرستون</p><p dir="RTL">-&nbsp; أياً من الأدویة الفمویة التي تستخدم لعلاج داء السكري (على سبیل المثال میتفورمین، أو أياً من الأدویة من مجموعة سلفونیل یوریا)</p><p dir="RTL">-&nbsp; العلاج بالأعشاب المعروف باسم جینكو بیلوبا (إن تزامن تناول آیبوبروفین مع جينكو بیلوبا یجعل فرصة تعرضك للنزیف بصورة أكثر سهولة)</p><p dir="RTL">-&nbsp; كولسترامین (یستخدم لعلاج ارتفاع مستویات الكولسترول)</p><p dir="RTL">-&nbsp; فوریكانازول أو فلوكونازول (أدویة مضادة للفطریات)</p><p dir="RTL"><strong>الكحول مع بروفینال</strong></p><p dir="RTL">قد تسبب الأدویة مثل <strong>بروفینال</strong> الشعور بالدوخة، النعاس، التعب ومشاكل في الرؤیة. قد یؤدي تناول الكحول إلى زیادة هذه التأثیرات.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبیعیة والخصوبة</strong></p><p dir="RTL">یرجى منك إخبار طبیبك المعالج، إذا كنت حاملاً،أو تعتقدین بأنك حاملا ً .</p><p dir="RTL">لا یوصى بتناول <strong>بروفینال</strong> خلال الثلث الأول والثاني من الحمل (الستة أشهر الأولى) إلا إذا استدعت الضرورة ذلك بصورة واضحة، كما یجب علیك عدم تناوله خلال الثلث الأخیر من الحمل (الثلاث أشهر الأخیرة). لا یوصى بتناول <strong>بروفینال</strong> أثناء فترة الرضاعة الطبیعیة.</p><p dir="RTL">قد یزید <strong>بروفینال</strong> من صعوبة حدوث الحمل. یرجى منك إخبار طبیبك المعالج إذا كنتِ تخططین لكي تصبحین حاملاً أو إذا كنت تعانین من مشاكل تعیق حدوث الحمل.</p><p dir="RTL"><strong>القیادة واستخدام الآلات</strong></p><p dir="RTL">إن بعض الأدویة على سبیل المثال <strong>بروفینال</strong> قد تسبب الشعور بالدوخة، النعاس، التعب ومشاكل في الرؤیة. یجب علیك عدم القیادة أو تشغیل الآلات، في حال تعرضك لمثل هذه التأثيرات. كما يجب عليك عدم القيام بأي مهام تتطلب اليقظة الذهنية. وينطبق ذلك بصفة خاصة في حال تناول هذا الدواء بالتزامن مع الكحول.</p><p dir="RTL"><strong>ما الذي تحتاج معرفته أیضا عن بروفینال</strong></p><p dir="RTL">یجب علیك عدم تناول <strong>بروفینال</strong> إذا كنت تعاني من الحساسیة تجاه الأسبرین. في حال ظهور طفح جلدي مفاجىء غیر متوقع، قرحة العینین، قرحة الفم أو صعوبة في التنفس أثناء فترة تناول الدواء، فیرجى منك التوقف عن تناوله واستشارة طبیبك المعالج للحصول على المشورة الطبية.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات بروفینال</strong></p><p dir="RTL">یحتوي<strong> بروفینال </strong>على<strong>:</strong></p><p dir="RTL">السوربیتول، ذو تأثير ملین طفیف.</p><p dir="RTL">السكروز، یجب أن یؤخذ ذلك بعین الاعتبار لدى المرضى الذین یعانون من داء السكري. قد یسبب ضرراً للأسنان.</p><p dir="RTL">یرجى منك استشارة طبیبك المعالج قبل تناول هذا الدواء، إذا قد أخبرك مسبقاً أنك تعاني من عدم القدرة على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استعمال أقل جرعة فعالة لأقصر فترة زمنية لازمة لتخفيف الأعراض. يرجى منك استشارة طبيبك المعالج على الفور، إذا كنت تعاني من العدوى واستمرار أو تفاقم الأعراض (على سبيل المثال الحمى والألم) (انظر البند رقم 2).</p><p dir="RTL">يجب عليك دائماً تناول هذا الدواء بدقة وفقاً لإرشادات طبيبك المعالج أو الصيدلي الذي تتعامل معه. يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، ما لم تكن متأكداً من ذلك.</p><p dir="RTL">من الممكن تناول <strong>بروفینال</strong> مع قلیل من الماء، ویفضل تناوله مع أو بعد الطعام.</p><p dir="RTL">تذكر أن ترج الزجاجة قبل الاستخدام.</p><p dir="RTL">یوصى بتناول آیبوبروفین مع الطعام من قبل المرضى الذین یعانون من حساسیة المعدة .</p><p dir="RTL"><strong>مقدار الجرعة الموصى بها:</strong></p><p dir="RTL"><strong>البالغون والمراهقون:</strong> یتراوح مقدار الجرعة الاعتیادیة من ٤ إلى ٦ ملاعق صغیرة سعة ٥ مللیلتر ثلاث مرات یومیاً. قد یلجأ طبیبك المعالج إلى زیادة أو تقلیل مقدار الجرعة المعطاة وذلك اعتماداً على الأعراض التي تعاني منها ، ولكن على أیة حال یجب ألا یتجاوز مقدار الجرعة الیومیة التي یجب تناولها عن ١٢٠ مللیلتر من المعلق الفموي ( ٢٤٠٠ ملغم).</p><p dir="RTL"><strong>الأطفال:</strong> یتراوح مقدار الجرعة الاعتیادیة للأطفال من ٢٠ ملغم إلى ٣٠ ملغم لكل كیلوغرام من وزن الجسم في الیوم، على جرعات مقسمة.</p><p dir="RTL"><strong>یمكن إعطاء الجرعة على النحو التالي:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>العمر / الوزن</strong></p></td><td><p dir="RTL"><strong>تكرار أخذ الجرعة</strong></p></td><td><p dir="RTL"><strong>مقدار الجرعة المفردة</strong></p></td></tr><tr><td><p dir="RTL">٣-٦ أشهر</p><p dir="RTL">(الذین یزنون ما یقارب٥-٧ كیلوغرام)</p></td><td><p dir="RTL">ما یصل إلى ٣ مرات في الیوم</p></td><td><p dir="RTL">٢,٥ مللیلتر &ndash; نصف ملعقة صغیرة ( ٥٠ ملغم)</p></td></tr><tr><td><p dir="RTL">٦-١٢ شهر</p><p dir="RTL">(الذین یزنون ما یقارب ٧-١٠ كیلوغرام)</p></td><td><p dir="RTL">٣ مرات في الیوم</p></td><td><p dir="RTL">٢,٥ مللیلتر &ndash; نصف ملعقة صغیرة ( ٥٠ ملغم)</p></td></tr><tr><td><p dir="RTL">١-٢سنة</p><p dir="RTL">(الذین یزنون ما یقارب ١٠- ١٤,٥ كیلوغرام)</p></td><td><p dir="RTL">من ٣ إلى ٤ مرات في الیوم</p></td><td><p dir="RTL">٢,٥ مللیلتر &ndash; نصف ملعقة صغیرة ( ٥٠ ملغم)</p></td></tr><tr><td><p dir="RTL">٣-٧سنوات</p><p dir="RTL">(الذین یزنون ما یقارب ١٤,٥-٢٥ كیلوغرام)</p></td><td><p dir="RTL">من ٣ إلى ٤ مرات في الیوم</p></td><td><p dir="RTL">٥ مللیلتر &ndash; ملعقة صغیرة واحدة ( ١٠٠ ملغم)</p></td></tr><tr><td><p dir="RTL">٨-١٢ سنة</p><p dir="RTL">(الذین یزنون ما یقارب ٢٥-٤٠ كیلوغرام)</p></td><td><p dir="RTL">من ٣ إلى ٤ مرات في الیوم</p></td><td><p dir="RTL">١٠ مللیلتر &ndash; ملعقتین صغیرتین (٢٠٠ ملغم)</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">قد یرغب الطبیب المعالج إلى زيادة مقدار تلك الجرعة إلى ٤٠ ملغم/كیلوغرام من وزن الجسم يومياً للأطفال الذین یعانون من التهاب المفاصل الحاد، في حال لزم ذلك. یجب عدم إعطاء أكثر من ٥٠٠ ملغم من <strong>بروفینال</strong> في الیوم للأطفال الذین یزنون أقل من ٣٠ كیلوغرام.</p><p dir="RTL"><strong>فئة كبار السن: </strong>یرجى منك الرجوع إلى الجرعة المخصصة للبالغین. یجب علیك استشارة طبیبك المعالج للحصول على المشورة الطبیة، إذا كنت تعاني من مشاكل في الكبد أو الكلى، فقد تكون بحاجة إلى إجراء تعدیل على مقدار الجرعة المعطاة.</p><p dir="RTL">قد یصاحب تناول معلق آیبوبروفین الشعور بالحرقة في الفم أو الحلق بصورة عابرة.</p><p dir="RTL">یجب تجنب تناول أياً من مسكنات الألم لفترة طویلة الأمد، نظراً لأنها قد تسبب في حدوث الصداع الذي یجب أن لا یتم علاجه عن طریق زیادة مقدار الجرعة من <strong>بروفینال</strong>. یرجى منك إخبار طبیبك المعالج في حال حدوث ذلك.</p><p dir="RTL"><strong>إذا تناولت بروفینال بجرعة أكبر مما یجب</strong></p><p dir="RTL">إذا كنت قد تناولت بروفينال بجرعة أكبر مما يجب أو تناول طفلاً هذا الدواء عن طريق الخطأ، فيجب عليك التواصل مع طبيبك المعالج أو توجه إلى أقرب مستشفى للحصول على المشورة الطبية حول المخاطر التي قد تتعرض لها والإجراءات التي يجب اتخاذها.&nbsp; قد تتضمن أعراض الجرعة المفرطة على غثيان، ألم في المعدة، تقيؤ (قد يكون مصحوباً بظهور دم)، صداع، طنين في الأذنين، ارتباك، اهتزاز في حركة العينين.&nbsp; في الجرعات العالية، تم الإبلاغ عن حدوث النعاس، ألم في الصدر، خفقان، فقدان الوعي والتشنجات (وبشكل رئيسي لدى الأطفال)، الشعور بالضعف، دوخة، ظهور دم في البول، الشعورة بالبرودة ومشاكل في التنفس.</p><p dir="RTL"><strong>إذا سهوت عن تناول بروفینال</strong></p><p dir="RTL">-&nbsp; تناول الجرعة التي قد سهوت عنها في أسرع وقت ممكن حال تذكرها، على الرغم من ذلك، یرجى منك التخطي عن الجرعة التي قد سهوت عن تناولها في حال اقتراب موعد تناول الجرعة التالیة.</p><p dir="RTL">-&nbsp; یجب عدم تناول جرعة مضاعفة لتعويض الجرعة التي قد سهوت عنها.</p><p dir="RTL"><strong>یرجى منك استشارة طبیبك المعالج أو الصیدلي الذي تتعامل معه، إذا كان لدیك أسئلة إضافیة حول استعمال هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، من الممكن أن يسبب هذا الدواء في حدوث تأثيرات جانبية، على الرغم من ذلك، قد لا تحدث لكل شخص. یرجى منك إخبار طبیبك المعالج أو الصیدلي الذي تتعامل معه في حال زیادة حدة أیاً من التأثیرات الجانبیة أو ملاحظة حدوث أیة تأثیرات جانبیة غیر مذكورة في هذه النشرة. یمكنك الحد من خطر حدوث التأثیرات الجانبیة للدواء عن طریق تناول أقل كمیة ممكنة من المعلق خلال أقصر فترة زمنیة لازمة للسيطرة على الأعراض.</p><p dir="RTL"><strong>التأثیرات الجانبیة الخطیرة</strong></p><p dir="RTL">-&nbsp; <strong>یرجى منك التوقف عن تناول بروفینال ورؤیة طبیبك المعالج على الفور في حال ملاحظة حدوث أیاً من التأثیرات الجانبیة التالیة - فقد تكون بحاجة إلى رعایة طبیة طارئة: </strong>صداع حاد، ارتفاع درجة الحرارة، تصلب الرقبة أو عدم القدرة على تحمل الضوء الساطع</p><p dir="RTL">-&nbsp; براز دموي</p><p dir="RTL">-&nbsp; براز ذو لون أسود</p><p dir="RTL">-&nbsp; قيء دموي أو قيء یحتوي على جزیئات داكنة اللون شبیهة بحبیبات القهوة</p><p dir="RTL">یرجى منك إخبار طبیبك المعالج والتوقف عن تناول هذا الدواء في حال ملاحظة حدوث أیا من ما یلي:</p><p dir="RTL">-&nbsp; تفاعلات فرط الحساسیة على سبیل المثال حدوث أزیز غیر مبرر، ضیق في التنفس، طفح جلدي، حكة أو ظهور كدمات</p><p dir="RTL">-&nbsp; حدوث ألم غیر مبرر في المعدة أو أعراض أخرى غیر طبیعیة في المعدة، عسر الهضم، حرقة في المعدة، الشعور بالإعیاء و/أو تقیؤ.</p><p dir="RTL">-&nbsp; إصفرار العینین و/أو الجلد.</p><p dir="RTL">-&nbsp; التهاب حاد في الحلق مصحوباً بحمى شدیدة (قد یكون ذلك أعراض حالة مرضیة تعرف باسم ندرة المحببات).</p><p dir="RTL">-&nbsp; عدم وضوح أو اضطراب الرؤیة أو رؤیة/سماع أشیاء غریبة.</p><p dir="RTL">-&nbsp; احتباس السوائل (على سبیل المثال تورم الكاحلین).</p><p dir="RTL">إن بعض الأدویة على سبیل المثال آیبوبروفین قد يرتبط استعمالها بارتفاع ضئیل لخطر حدوث النوبات القلبیة (احتشاء عضلة القلب) أو السكتة الدماغیة قد یسبب آیبوبروفین بصورة نادرة جداً، التهاب السحایا العقیم (التهاب الغشاء الواقي المحیط بالدماغ).</p><p dir="RTL">من الممكن حدوث تفاعل جلدي شديد يعرف باسم الطفح الجلدي المصحوب بفرط الحمضات والأعراض الجهازية. تتضمن أعراض حدوث ذلك على: طفح جلدي، حمى، تورم الغدد الليمفاوية وارتفاع مستويات الخلايا الحمضية (إحدى أنواع خلايا الدم البيضاء).</p><p dir="RTL">طفح جلدي أحمر اللون واسع النطاق مصحوباً بتقرحات الجلد ونتوءات تحت الجلد وتقرحات الذي يصيب بصورة رئيسية ثنايا الجلد، الجذع والأطراف العلوية، وكما يكون مصحوباً بحمى في بداية فترة تلقي العلاج (طفح البثري الحاد المعمم). يجب عليك التوقف عن تناول بروفينال، في حال حدوث أياً من هذه الأعراض وطلب الرعاية الطبية على الفور. انظر البند رقم 2.</p><p dir="RTL">قد یعمل آیبوبروفین على إخفاء علامات حدوث العدوى.</p><p dir="RTL"><strong>قد تتضمن التأثیرات الجانبیة الأخرى الناجمة عن هذا الدواء على:</strong></p><p dir="RTL">-&nbsp; غثیان، تقیؤ، إسهال، الشعور بالانتفاخ (ریح) إمساك، ألم في المعدة</p><p dir="RTL">-&nbsp; تقرح الفم</p><p dir="RTL">-&nbsp; تقرح الإثنى عشر</p><p dir="RTL">-&nbsp; انثقاب المعدة</p><p dir="RTL">-&nbsp; تفاقم حالة التهاب القولون أو مرض كرون</p><p dir="RTL">-&nbsp; التهاب في بطانة المعدة</p><p dir="RTL">-&nbsp; التهاب البنكریاس</p><p dir="RTL">-&nbsp; الشعور بالحرقة في الفم أو الحلق</p><p dir="RTL">-&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp; قصور القلب</p><p dir="RTL">-&nbsp; انسداد في الأنف أو سیلان الأنف (التهاب الأنف)</p><p dir="RTL">-&nbsp; اضطرابات الدم على سبیل المثال انخفاض تعداد أنواع مختلفة من الخلایا في الدم</p><p dir="RTL">-&nbsp; الصعوبة في النوم، القلق، اكتئاب، ارتباك</p><p dir="RTL">-&nbsp; صداع، تنمیل أو تخدر، دوخة، الشعور بالنعاس، الشعور بالتعب، الشعور بالإعیاء بصورة عامة</p><p dir="RTL">-&nbsp; عدم وضوح الرؤیة، التهاب العصب البصري</p><p dir="RTL">-&nbsp; اضطراب في التوازن الذي یجعل حركتك غیر متزنة ومترنحة والشعور بالدوخة، الدوار، طنین في الأذنین، مشاكل في حاسة السمع</p><p dir="RTL">-&nbsp; اضطرابات الكبد على سبیل المثال التهاب الكبد أو الیرقان</p><p dir="RTL">-&nbsp; اضطرابات جلدیة على سبیل المثال زیادة الحساسیة تجاه الضوء وتفاعلات حادة (على سبیل المثال تقرح الجلد، الفم، العینین والأعضاء التناسلیة)</p><p dir="RTL">-&nbsp; اضطرابات الكلى، بما في ذلك انخفاض وظائف الكلى وقصور الكلى</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&bull; المملكة العربية السعودية</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;رقم الفاكس:&nbsp; </strong>&nbsp;7662-205-11-966+</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على:</strong> 2038222-11-966+،</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;وصلة هاتف:</strong>2340-2356-2317</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;مركز اتصال الهيئة العامة للغذاء والدواء : </strong>19999</p><p dir="RTL">&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;الموقع الإلكتروني:</strong> www.sfda.gov.sa/npc</p><p dir="RTL"><strong>&bull; دول مجلس التعاون الخليجي الأخرى: يرجى الاتصال بالجهات المختصة ذات الصلة</strong></p><p dir="RTL"><strong>إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp; یحفظ بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">-&nbsp; یجب عدم تناول هذا الدواء بعد تاریخ انتهاء الصلاحیة المذكور على العبوة الخارجیة والملصق الداخلي للزجاجة.</p><p dir="RTL">-&nbsp; يحفظ في درجة حرارة أقل من &ordm;30م، بعيداً عن الضوء. بعد فتح العبوة، يُستخدم خلال شهر واحد.</p><p dir="RTL">-&nbsp; یجب عدم تناول هذا الدواء إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp; یجب عدم التخلص من الأدویة عبر المیاه المبتذلة (میاه الصرف الصحي) أو النفایات المنزلیة. اسأل الصیدلي الذي تتعامل معه عن كیفیة التخلص من الأدویة التي لم تعد بحاجة إلیها. ستساعد هذه الإجراءات على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي آیبوبروفین. تحتوي كل ملعقة صغیرة ( ٥ مللیلتر) من المعلق على ١٠٠ ملغم من آیبوبروفین.</p><p dir="RTL">المواد الغير فعالة الأخرى: سكروز، بنزوات الصودیوم، سكارین الصودیوم، صودیوم إدیتا، جلیسیرول، سوربیتول، صمغ الزانثان، سلیلوز، بولي سوربات، حمض الستریك، إف دي وسي أحمر رقم ٤٠ ، نكهة الفواكه، نكهة الفراولة وماء منقى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یتوفر معلق <strong>بروفینال</strong> في عبوات تحتوي كلاً منها على زجاجة واحدة (سعة ٦٠ مللیلتر، ١١٠ مللیلتر أو ١٣٥ مللیلتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية&quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/11/2020م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Profinal 100mg/5mL Paediatric Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each teaspoonful (5mL) of the suspension contains:
Item No.  Material Name 	             Scale (mg/5mL)
		
	Active Ingredient:	
1.		Ibuprofen (Coarse)	    100.00
		
	Inactive Ingredients:	
1.		Sucrose (Sugar syrup)   4200.00
2.		Sodium benzoate 	    10.00
3.		Saccharin sodium 	    5.00
4.		Sodium EDTA 	            5.00
5.		Glycerol 	                    500.00
6.		Sorbitol 70% solution    500.00
7.		Xanthan gum 	           8.00
8.		Avicel RC  591	          20.00
9.		Tween 80	                  5.00
10.		Citric acid 	                 8.50
11.		Colour FD&C red 40	1.25
12.		All fruit flavour 	        7.50
13.		Strawberry flavour 	5.00
14.		Purified water 	        q.s. to 5mL

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral Suspension
Description: Red homogenous viscous suspension, with fruity odour and sweet palatable taste. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Profinal</strong> Paediatric Oral Suspension is indicated in the management of various arthroses such as rheumatoid arthritis (including juvenile rheumatoid arthritis or Still&#39;s Disease) and osteoarthritis, fibrositis, ankylosing and other muscular syndromes such as low back pain, soft tissue trauma and various inflammations of tendon, joint capsules and ligaments.</p><p>As an analgesic in the relief of mild to moderate pain.</p><p>Ibuprofen is indicated for the treatment of pyrexia in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology:</u></strong></p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (<em>see section 4.4)</em>.</p><p><strong><u>Adults and adolescents older than 12 years (&ge; 40kg):</u></strong></p><p>The recommended dosage of ibuprofen is 1200-1800 mg daily in divided doses. Some patients can be maintained on 600-1200 mg daily. Total daily dose should not exceed 2400 mg.</p><p><strong><u>Paediatric Population: </u></strong></p><p>The recommended dose of ibuprofen is 20-30 mg per kg of bodyweight daily in divided doses. This can be achieved by using the suspension as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Age/weight</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Single dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>3-6 months (~5-7kg)</p></td><td style="vertical-align:top"><p>Up to 3 times a day</p></td><td style="vertical-align:top"><p>2.5ml(50mg)</p></td></tr><tr><td style="vertical-align:top"><p>6-12 months (~7-10kg)</p></td><td style="vertical-align:top"><p>3 times a day</p></td><td style="vertical-align:top"><p>2.5ml (50mg)</p></td></tr><tr><td style="vertical-align:top"><p>1 to 2 years (~10-14.5kg)</p></td><td style="vertical-align:top"><p>3 to 4 times a day</p></td><td style="vertical-align:top"><p>2.5ml (50mg)</p></td></tr><tr><td style="vertical-align:top"><p>3 to 7 years (~14.5-25kg)</p></td><td style="vertical-align:top"><p>3 to 4 times a day</p></td><td style="vertical-align:top"><p>5ml (100mg)</p></td></tr><tr><td style="vertical-align:top"><p>8 to 12 years (~25-40kg)</p></td><td style="vertical-align:top"><p>3 to 4 times a day</p></td><td style="vertical-align:top"><p>10ml (200mg)</p></td></tr></tbody></table><p>In juvenile rheumatoid arthritis, the daily dosage may be increased to 40 mg/kg bodyweight daily in severe cases. In children weighing less than 30 kg, the total daily dose of ibuprofen should not exceed 500 mg.</p><p>The suspension is indicated in short-term use for the treatment of pyrexia in children over 3 months of age. Ibuprofen is not recommended for children weighing less than 5 kilograms.</p><p><strong>Elderly Population:</strong></p><p>No special dosage modifications are required, unless renal or hepatic function is impaired, in which case dosage should be assessed individually.</p><p><strong>Renal impairment</strong></p><p>No dose reduction is required in patients with mild to moderate impairment to renal function (patients with severe renal insufficiency, see section 4.3).</p><p><strong>Hepatic impairment</strong></p><p>No dose reduction is required in patients with mild to moderate impairment to hepatic function (patients with severe hepatic dysfunction, see section 4.3).</p><p><strong><u>Method of administration:</u></strong></p><p>In order to achieve a faster onset of action, the dose may be taken on an empty stomach. It is recommended that patients with sensitive stomachs take ibuprofen with food. Ensure the bottle is thoroughly shaken before use. A transient sensation of burning in the mouth or throat may occur with ibuprofen suspension.</p><p>For oral administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Known hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	Ibuprofen should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking acetylsalicylic acid/asprin or other NSAIDs.
	Severe heart failure (NYHA IV).
	Severe liver failure.
	Severe renal failure (glomerular filtration below 30mL/min).
	Conditions involving an increased tendency or active bleeding.
	History of gastrointestinal bleeding or perforation, related to previous NSAID therapy.
	Active, or history of ulcerative colitis, Crohn's disease, recurrent peptic ulceration or gastrointestinal haemorrhage (defined as two or more distinct episodes of proven ulceration or bleeding)
	During the third trimester of pregnancy (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (<em>see section 4.2).</em></p><p>Patients treated with NSAIDs long-term should undergo regular medical supervision to monitor for adverse events.</p><p>Caution is required if ibuprofen paediatric oral suspension is administered to patients suffering from, or with a previous history of, bronchial asthma since ibuprofen has been reported to cause bronchospasm in such patients.</p><p>Caution is required in patients with renal, hepatic or cardiac impairment since the use of NSAIDs may result in deterioration of renal function. The dose should be kept as low as possible and assessment of renal function should be monitored prior to the initiation of therapy and regularly thereafter, especially in long-term treated patients.</p><p>Caution is required in patients with a history of heart failure and/or hypertension as fluid retention and oedema has been reported in association with NSAID therapy.</p><p>The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of ibuprofen should be considered.</p><p>As with other NSAIDs, ibuprofen may mask the signs of infection.</p><p><strong><u>Masking of symptoms of underlying infections </u></strong></p><p>Ibuprofen can mask symptoms of infection, which may lead to delayed initiation of appropriate treatment and thereby worsening the outcome of the infection. This has been observed in bacterial community acquired pneumonia and bacterial complications to varicella. When ibuprofen is administered for fever or pain relief in relation to infection, monitoring of infection is advised. In non-hospital settings, the patient should consult a doctor if symptoms persist or worsen.</p><p><strong>Profinal</strong> paediatric 100mg/5ml oral suspension contains sucrose and sorbitol. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficinency should not take this medicine. This should also be taken into account in patients with diabetes mellitus. May be harmful to the teeth.</p><p>The use of ibuprofen with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided due to the potential for additive effects.</p><p>On prolonged use of any painkillers, headache may occur that must not be treated with increased doses of the medicinal product.</p><p>Through concomitant consumption of alcohol, active substance-related undesirable effects, particularly those that concern the gastrointestinal tract or the central nervous system, may be increased on use of NSAIDs.</p><p><strong><u>Elderly population</u></strong></p><p>Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal.</p><p><strong><u>Gastrointestinal bleeding, ulceration and perforation</u></strong></p><p>GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p>The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation&nbsp;<em>(See section 4.3)</em>, and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (<em>See below and section 4.5)</em>.</p><p>The concomitant administration of ibuprofen and other NSAIDs, including cyclooxygenase-2 (Cox-2) selective inhibitors, should be avoided due to the increased the increased risk of ulceration or bleeding (<em>See below and section 4.5</em>).</p><p>Patients with a history of GI disease, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.</p><p>Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid/aspirin (<em>See section 4.5)</em>.</p><p>When GI bleeding or ulceration occurs in patients receiving ibuprofen, the treatment should be withdrawn.</p><p><strong><u>Respiratory disorders</u></strong></p><p>Caution is required if ibuprofen is administered to patients suffering from, or with a previous history of, bronchial asthma, chronic rhinitis or allergic diseases since ibuprofen has been reported to cause bronchospasm, urticaria or angioedema in such patients</p><p><strong><u>Cardiovascular and cerebrovascular effects</u></strong></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p>Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. &le; 1200mg day) is associated with an increased risk of arterial thrombotic events.</p><p>Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400mg/day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of ibuprofen (2400mg/day) are required.</p><p><strong><u>Renal effects</u></strong></p><p>Caution should be used when initiating treatment with ibuprofen in patients with considerable dehydration.</p><p>There is a risk of renal impairment especially in dehydrated children, adolescents and the elderly.</p><p>As with other NSAIDs, long-term administration of ibuprofen has resulted in renal papillary necrosis and other renal pathological changes. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandins formation and, secondarily, in renal blood flow, which may cause renal failure. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those who are taking diuretics and ACE inhibitors and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pre-treatment state.</p><p><strong><u>Haematological effects</u></strong></p><p>As NSAIDs can interfere with platelet function and may prolong bleeding time, ibuprofen should be used with caution in patients with intracranial haemorrhage and bleeding diathesis.</p><p><strong><u>Dermatological effects</u></strong></p><p>Severe skin reactions</p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at the highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalised exanthematous pustulosis (AGEP) has been reported in relation to ibuprofen- containing products. Ibuprofen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>Exceptionally, varicella can be at the origin of serious cutaneous and soft tissues infectious complications. To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of Ibuprofen in case of varicella.</p><p><strong><u>Aseptic meningitis</u></strong></p><p>Aseptic meningitis has been observed on rare occasions in patients with ibuprofen therapy. Although it is probably more likely to occur in patients with systematic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>It is considered unsafe to take NSAIDs in combination with warfarin or heparin unless under direct medical supervision.</strong></p><p>Care should be taken in patients treated with any of the following drugs as interactions have been reported:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>Concomitant use of ibuprofen with:</strong></p></td><td style="vertical-align:top"><p><strong>Possible effects:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Other NSAIDs including cyclooxygenase-2 selective inhibitors</p></td><td style="vertical-align:top"><p>Concomitant use with other NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided due to the potential for additive effects</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac glycosides</p></td><td style="vertical-align:top"><p>NSAIDs may exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroids</p></td><td style="vertical-align:top"><p>Increased risk of gastrointestinal ulceration or bleeding with NSAIDs</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p></td><td style="vertical-align:top"><p>NSAIDs may enhance the effects of anticoagulants, such as warfarin</p></td></tr><tr><td style="vertical-align:top"><p>Antiplatelet agents &amp; selective serotonin-reuptake inhibitors (SSRIs), e.g. clopidogrel and ticlopidine</p></td><td style="vertical-align:top"><p>Increased risk of gastrointestinal bleeding with NSAIDs</p></td></tr><tr><td style="vertical-align:top"><p>Acetylsalicylic acid/aspirin</p></td><td style="vertical-align:top"><p>As with other products containing NSAIDs, concomitant administration of ibuprofen and acetylsalicylic acid/aspirin is not generally recommended because of the potential of increased adverse effects.</p><p>Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid/aspirin on platelet aggregation when they are dosed concomitantly. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular long-term use of ibuprofen may reduce the cardioprotective effect of low-dose aspirin (acetylsalicylic acid) cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use&nbsp;<em>(see section 5.1)</em></p></td></tr><tr><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>NSAIDs may decrease elimination of lithium</p></td></tr><tr><td style="vertical-align:top"><p>Anti-hypertensive, beta-blockers and diuretics</p></td><td style="vertical-align:top"><p>NSAIDs may reduce the effect of anti-hypertensives, such as ACE inhibitors, angiotensin-II receptor antagonists, beta-blockers and diuretics.</p><p>Diuretics can also increase the risk of nephrotoxicity of NSAIDs</p></td></tr><tr><td style="vertical-align:top"><p>Methotrexate</p></td><td style="vertical-align:top"><p>NSAIDs may inhibit the tubular secretion of methotrexate and reduce clearance of methotrexate.</p></td></tr><tr><td style="vertical-align:top"><p>Cyclosporine</p></td><td style="vertical-align:top"><p>Increased risk of nephrotoxicity with NSAIDs</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus</p></td><td style="vertical-align:top"><p>Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus</p></td></tr><tr><td style="vertical-align:top"><p>Zidovudine</p></td><td style="vertical-align:top"><p>Increased risk of haematological toxicity with NSAIDs are given with zidovudine. There is evidence of an increased risk of hemarthrosis and hematoma in HIV(+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen</p></td></tr><tr><td style="vertical-align:top"><p>Quinolone antibiotics</p></td><td style="vertical-align:top"><p>Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.</p></td></tr><tr><td style="vertical-align:top"><p>CYP2C9 inhibitors</p></td><td style="vertical-align:top"><p>Concomitant administration of ibuprofen with CYP2C9 inhibitors may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased S(+)- ibuprofen exposure by approximately 80 to 100% has been shown. Reduction of the ibuprofen dose should be considered when potent CYP2C9 inhibitors are administered concomitantly, particularly when high-dose ibuprofen is administered with either voriconazole or fluconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Sulfonylureas</p></td><td style="vertical-align:top"><p>NSAIDs may potentiate the effects of sulfonylurea medications. There have been rare reports of hypoglycaemia in patients on sulfonylurea medications receiving ibuprofen.</p></td></tr><tr><td style="vertical-align:top"><p>Cholestyramine</p></td><td style="vertical-align:top"><p>The concomitant administration of ibuprofen and cholesytramine may reduce the absorption of ibuprofen in the gastrointestinal tract. However, the clinical significance is unknown.</p></td></tr><tr><td style="vertical-align:top"><p>Aminoglycosides</p></td><td style="vertical-align:top"><p>NSAIDs may decrease the excretion of aminoglycosides.</p></td></tr><tr><td style="vertical-align:top"><p>Herbal extracts</p></td><td style="vertical-align:top"><p>Ginkgo biloba may potentiate the risk of bleeding with NSAIDs.</p></td></tr><tr><td style="vertical-align:top"><p>Mifepristone</p></td><td style="vertical-align:top"><p>A decrease in the efficacy of the medicinal product can theoretically occur due to the antiprostaglandin properties of NSAIDs including acetylsalicylic acid. Limited evidence suggests that coadministration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Fertility</u></strong></p><p>The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of ibuprofen should be considered.</p><p><strong><u>Pregnancy</u></strong></p><p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, the administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation losses and embryo/foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be given unless clearly necessary. If ibuprofen is used by a woman attempting to conceive, or during the first or second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to the following:</p><p>&sect; Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension)</p><p>&sect; Renal dysfunction, which may progress to renal failure with oligohydramnios.</p><p>At the end of pregnancy, prostaglandin synthesis inhibitors may expose the mother and the neonate to the following:</p><p>&sect; Possible prolongation of bleeding time</p><p>&sect; Inhibition of uterine contractions, which may result in delayed or prolonged labour.</p><p>Consequently, ibuprofen is contraindicated during the third trimester of pregnancy.</p><p><strong>Labour and delivery:</strong></p><p>Administration of ibuprofen is not recommended during labour and delivery. The onset of labour may be delayed and the duration increased with a greater bleeding tendency in both mother and child.</p><p><strong><u>Breastfeeding</u></strong></p><p>In limited studies to date, ibuprofen appears in breast milk in very low concentrations. Ibuprofen is not recommended for use in nursing mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. This applies to a greater extent in combination with alcohol. If affected, patients should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Gastrointestinal disorders:</u></strong></p><p>The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (<em>see section 4.4).&nbsp;</em>Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&#39;s disease (<em>see section 4.4)</em>&nbsp;have been reported following administration. Less frequently, gastritis, duodenal ulcer &amp; gastric ulcer and gastrointestinal perforation have been observed.</p><p>A transient sensation of burning in the mouth or throat may occur with ibuprofen suspension.</p><p><strong><u>Immune system disorders:</u></strong></p><p>Hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of (a) non-specific allergic reaction and anaphylaxis, (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, very rarely, erythema multiforme, bullous dermatoses (including Stevens-Johnson syndrome and toxic epidermal necrolysis).</p><p><strong><u>Infections and infestations:</u></strong></p><p>Exacerbation of infection-related inflammations (e.g. development of necrotising fasciitis) coinciding with the use of NSAIDs has been described. If signs of an infection occur or get worse during the use of ibuprofen, the patient is therefore recommended to go to a doctor without delay.</p><p><strong><u>Skin and subcutaneous tissue disorders:</u></strong></p><p>In exceptional cases, severe skin infections and soft-tissue complications may occur during a varicella infection (see also Infections and infestations and section 4.4)</p><p><strong><u>Cardiac disorders and vascular disorders</u></strong><u>:</u></p><p>Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. Clinical trial studies suggest that use of ibuprofen, particularly at high dose (2400 mg/day), may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) <em>(see section 4.4).</em></p><p>The following are adverse reactions possibly related to ibuprofen, displayed by MedDRA frequency convention and system organ classification. Frequency groupings are classified according to the subsequent conventions: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000) and Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rhinitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Meningitis aseptic (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Phychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Insomnia, anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Depression, confusional state</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Optic neuritis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Visual impairment</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Toxic optic neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hearing impaired, tinnitus, vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Asthma, bronchospasm, dyspnea</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, hematemesis, gastrointestinal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastritis, duodenal ulcer, gastric ulcer, mouth ulceration, gastrointestinal perforation</p></td></tr><tr><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Exacerbation of Colitis and Crohn&#39;s disease</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatitis, jaundice, hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Hepatic failure</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria, pruritus, purpura, angioedema, photosensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Severe forms of skin reactions (e.g. Erythema multiforme, bullous reactions including Stevens-Johnson syndrome, and toxic epidermal necrolysis).</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), Acute generalised exanthematous pustulosis (AGEP)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nephrotoxicity in various forms, e.g. Tubulointerstitial nephritis, nephrotic syndrome and renal failure</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Edema</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Cardiac failure, myocardial infarction&nbsp;<em>(see also section 4.4)</em></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr></tbody></table><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC at </strong>+966-11-2038222, <strong>Exts: </strong>2317-2356-2340</p><p><strong>Reporting Hotline: </strong>19999</p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p><p>&sect; <strong>Other GCC States: </strong>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Toxicity:</u></strong></p><p>Signs and symptoms of toxicity have generally not been observed at doses below 100 mg/kg in children or adults. However, supportive care may be needed in some cases. Children have been observed to manifest signs and symptoms of toxicity after ingestion of 400 mg/kg or greater.</p><p><strong><u>Symptoms:</u></strong></p><p>Most patients who have ingested significant amounts of ibuprofen will manifest symptoms within 4 to 6 hours. The most frequently reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsion, and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea and depression of the CNS and respiratory system have also been rarely reported. Cardiovascular toxicity, including hypotension, bradycardia and tachycardia, has been reported. In cases of significant overdose, renal failure and liver damage are possible. Large overdoses are generally well tolerated when no other drugs are being taken.</p><p><strong><u>Treatment:</u></strong></p><p>There is no specific antidote for ibuprofen overdose. Gastric emptying followed by supportive measures is recommended if the quantity ingested exceeds 400 mg/kg within the previous hour. For the most current information, contact the local poison control centre.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic classification: </strong>Anti-inflammatory and anti-rheumatic products, non-steroidal, propionic acid derivatives.</p><p><strong>ATC Code:</strong> M01AE01</p><p>Ibuprofen is a propionic acid derivative, non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory and anti-pyretic effects. The drug&#39;s therapeutic effect as a non-steroidal anti-inflammatory drug is thought to result from its inhibitory activity on the enzyme cyclo-oxygenase, which results in a marked reduction in prostaglandin synthesis. These properties provide symptomatic relief of inflammation, pain and fever.</p><p>Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid/aspirin on platelet aggregation when they are dosed concomitantly. Some pharmacodynamics studies show that, when single doses of ibuprofen 400mg were taken within 8 h before or within 30 min after immediate release acetylsalicylic acid/aspirin dosing (81mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. Although there are uncertainties regarding extrapolation of these data to the clinical the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid/aspirin cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ibuprofen is a racemic mixture of [+]S- and [-]R-enantiomers.</p><p>Studies including a standard meal show that food does not markedly affect total bioavailability.</p><p><strong><u>Absorption</u></strong><u>:</u></p><p>Ibuprofen is rapidly absorbed from the gastrointestinal tract with a bioavailability of 80-90%. Peak serum concentrations occur one to two hours after administration of immediate release formulations.</p><p><strong><u>Distribution:</u></strong></p><p>Ibuprofen is extensively bound to plasma proteins (99%). Ibuprofen has a small volume of distribution being about 0.12-0.2 L/kg in adults.</p><p><strong><u>Biotransformation:</u></strong></p><p>Ibuprofen is rapidly metabolized in the liver through cytochrome P450, preferentially CYP2C9, to two primary inactive metabolites, 2-hydroxyibuprofen and 3-carboxyibuprofen. Following oral ingestion of the drug, slightly less than 90% of an oral dose if ibuprofen can be accounted for in the urine as oxidative metabolites and their glucuronic conjugates. Very little ibuprofen is excreted unchanged in the urine.</p><p><strong><u>Elimination:</u></strong></p><p>Excretion by the kidney is both rapid and complete. The elimination half-life of immediate release formulations is approximately two hours. The excretion of ibuprofen is virtually complete 24 hours after the last dose.</p><p><strong><u>Special populations:</u></strong></p><p><strong>Elderly</strong></p><p>Given that no renal impairment exists, there are only small, clinically insignificant differences in the pharmacokinetic profile and urinary excretion between young and elderly.</p><p><strong>Paediatric population</strong></p><p>The systemic exposure of ibuprofen following weight adjusted therapeutic dosage (5mg/kg to 10mg/kg bodyweight) in children aged 1 year or over, appears similar to that in adults. Children 3 months to 2.5 years appeared to have a higher volume of distribution (L/kg) and clearance (l/kg/h) of ibuprofen than did children ˃2.5 to 12 years of age.</p><p><strong>Renal impairment</strong></p><p>For patients with mild renal impairment, increased plasma level of (S)-ibuprofen, higher AUC values for (S)-ibuprofen and increased enantiomeric AUC(S/R) ratios as compared with healthy controls have been reported. In end-stage renal disease patients receiving dialysis, the mean free fraction of ibuprofen was about 3% compared with about 1% in healthy volunteers. Severe impairment of renal function may result in accumulation of ibuprofen metabolites. The significance of this effect is unknown. The metabolites can be removed by haemodialysis (see sections 4.2, 4.3 and 4.4).</p><p><strong>Hepatic impairment</strong></p><p>Alcoholic liver disease with mild to moderate hepatic impairment did not result in substantially altered pharmacokinetic parameters.</p><p>In cirrhotic patients with moderate hepatic impairment (Child Pugh&#39;s score 6-10) treated with racemic ibuprofen, an average 2-fold prolongation of the half-life was observed and the enantiomeric AUC ratio (S.R) was significantly lower compared to healthy controls, suggesting an impairment of metabolic inversion of (R)-ibuprofen to the active (S)-enantiomer (see sections 4.2, 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no preclinical data of relevant for the safety assessments, apart from what has already been taken into account.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>1. Sucrose (Sugar Syrup)</p></td></tr><tr><td style="vertical-align:top"><p>2. Sodium Benzoate</p></td></tr><tr><td style="vertical-align:top"><p>3. Saccharin Sodium</p></td></tr><tr><td style="vertical-align:top"><p>4. Sodium EDTA</p></td></tr><tr><td style="vertical-align:top"><p>5. Glycerol</p></td></tr><tr><td style="vertical-align:top"><p>6. Sorbitol 70% Solution</p></td></tr><tr><td style="vertical-align:top"><p>7. Xanthan Gum</p></td></tr><tr><td style="vertical-align:top"><p>8. Avicel RC 591</p></td></tr><tr><td style="vertical-align:top"><p>9. Tween 80</p></td></tr><tr><td style="vertical-align:top"><p>10. Citric Acid</p></td></tr><tr><td style="vertical-align:top"><p>11. Colour FD&amp;C Red 40</p></td></tr><tr><td style="vertical-align:top"><p>12. All Fruit Flavour</p></td></tr><tr><td style="vertical-align:top"><p>13. Strawberry Flavour</p></td></tr><tr><td style="vertical-align:top"><p>14. Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Profinal Suspension 110mL
Before Opening: 36 months from the date of manufacturing
After Opening: one month 
Profinal Suspension 135mL
Before Opening: 24 months from the date of manufacturing
After Opening: one month 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C, protected from light</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Pack of 110mL:</strong> Pack of 110 mL suspension in a sealed, labelled glass bottle, packed in a printed carton along with dosing cup and a leaflet.</p><p>&sect; <strong>Pack of 135mL:</strong> Pack of 135 mL suspension in a sealed, labelled glass bottle, packed in a printed carton along with dosing cup and a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11. November. 2020

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>